- Home
- PVLA vs TXMD Comparison
PVLA vs TXMD Comparison
Compare PVLA & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- TXMD
- Stock Information
- Founded
- PVLA 2015
- TXMD 2008
- Country
- PVLA United States
- TXMD United States
- Employees
- PVLA N/A
- TXMD N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- PVLA Health Care
- TXMD Health Care
- Exchange
- PVLA Nasdaq
- TXMD Nasdaq
- Market Cap
- PVLA 15.9M
- TXMD 12.8M
- IPO Year
- PVLA N/A
- TXMD N/A
- Fundamental
- Price
- PVLA N/A
- TXMD $1.11
- Analyst Decision
- PVLA
- TXMD
- Analyst Count
- PVLA 0
- TXMD 0
- Target Price
- PVLA N/A
- TXMD N/A
- AVG Volume (30 Days)
- PVLA 47.8K
- TXMD 19.7K
- Earning Date
- PVLA 01-01-0001
- TXMD 11-12-2024
- Dividend Yield
- PVLA N/A
- TXMD N/A
- EPS Growth
- PVLA N/A
- TXMD N/A
- EPS
- PVLA N/A
- TXMD N/A
- Revenue
- PVLA N/A
- TXMD $1,596,000.00
- Revenue This Year
- PVLA N/A
- TXMD $605.07
- Revenue Next Year
- PVLA N/A
- TXMD $1.11
- P/E Ratio
- PVLA N/A
- TXMD N/A
- Revenue Growth
- PVLA N/A
- TXMD N/A
- 52 Week Low
- PVLA $6.20
- TXMD $1.05
- 52 Week High
- PVLA $22.32
- TXMD $2.75
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- TXMD 25.35
- Support Level
- PVLA N/A
- TXMD $1.05
- Resistance Level
- PVLA N/A
- TXMD $1.30
- Average True Range (ATR)
- PVLA 0.00
- TXMD 0.07
- MACD
- PVLA 0.00
- TXMD -0.01
- Stochastic Oscillator
- PVLA 0.00
- TXMD 18.75
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.